{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:11Z","timestamp":1792643951663,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a broad spectrum of molecular alterations that influence clinical outcomes.\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations define one of the most lethal subtypes of AML, driving resistance to nearly all available treatment modalities, including venetoclax plus azacitidine (VenAza). Yet, the molecular basis of this resistance, beyond affecting transactivation of BCL-2 family genes, has remained elusive. Here, we demonstrate that VenAza treatment leads to reduced transcriptional upregulation of the p53 signaling pathway in\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant\/deficient AML compared to wild-type AML. Functionally,\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant\/deficient AML exhibits selective failure in apoptosis induction rather than impaired G1 arrest or senescence. Despite inhibition of pro-apoptotic BAX and selective enrichment for MCL-1 in\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant isogenic AML cells, compensatory upregulation of BIM preserved functional mitochondrial outer membrane permeabilization (MOMP).\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant primary AML tumors at baseline also had retained capacity for MOMP. Instead,\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant AML exhibited disruption in caspase-3\/7 activation to evade apoptosis after VenAza therapy \u2013 decoupling the mitochondrial and executioner phases of apoptosis. Importantly, this \u201cpost-MOMP brake\u201d is not a bystander effect but itself a driver of VenAza and chemotherapy resistance in\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant\/deficient AML. This previously unrecognized mechanistic insight shifts the focus from mitochondrial priming to terminal caspase blockade in\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant AML and opens the door for urgently needed therapeutic strategies that reignite apoptosis at its execution point.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09087-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:07:00Z","timestamp":1785200820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutations drive therapy resistance through post-mitochondrial caspase blockade"],"prefix":"10.1038","volume":"17","author":[{"given":"Ahmed M.","family":"Mamdouh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fizza","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse A.","family":"Olesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Qi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaista","family":"Jasdanwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Si En","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Tan En","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Al Nayem","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishtha","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Hogdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman R.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-9013","authenticated-orcid":false,"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-2894","authenticated-orcid":false,"given":"Koji","family":"Itahana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2617-5082","authenticated-orcid":false,"given":"Shruti","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"9087_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s13402-019-00452-0","volume":"42","author":"A Toma-Jonik","year":"2019","unstructured":"Toma-Jonik A, Vydra N, Janus P, Wid\u0142ak W. Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction. Cell Oncol Dordr. 2019;42:579\u201389. https:\/\/doi.org\/10.1007\/s13402-019-00452-0.","journal-title":"Cell Oncol Dordr"},{"key":"9087_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170:1062\u201378. https:\/\/doi.org\/10.1016\/j.cell.2017.08.028.","journal-title":"Cell"},{"key":"9087_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/gcc.22796","volume":"58","author":"K Barbosa","year":"2019","unstructured":"Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer. 2019;58:875\u201388. https:\/\/doi.org\/10.1002\/gcc.22796.","journal-title":"Genes Chromosomes Cancer"},{"key":"9087_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"key":"9087_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376:536\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1611604.","journal-title":"N Engl J Med"},{"key":"9087_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-784","volume":"15","author":"S Feurstein","year":"2014","unstructured":"Feurstein S, R\u00fccker FG, Bullinger L, Hofmann W, Manukjan G, G\u00f6hring G, et al. Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics. 2014;15:784. https:\/\/doi.org\/10.1186\/1471-2164-15-784.","journal-title":"BMC Genomics"},{"key":"9087_CR7","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, et al. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022;28:5272\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1183.","journal-title":"Clin Cancer Res"},{"key":"9087_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"key":"9087_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007\u201312. https:\/\/doi.org\/10.1182\/blood-2018-03-828269.","journal-title":"Blood"},{"key":"9087_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study. J Clin Oncol. 2019;37:1277\u201384. https:\/\/doi.org\/10.1200\/JCO.18.01600.","journal-title":"J Clin Oncol"},{"key":"9087_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"9087_CR12","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/cncr.33689","volume":"127","author":"K Kim","year":"2021","unstructured":"Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127:3772\u201381. https:\/\/doi.org\/10.1002\/cncr.33689.","journal-title":"Cancer"},{"key":"9087_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10:107. https:\/\/doi.org\/10.1038\/s41408-020-00376-1.","journal-title":"Blood Cancer J"},{"key":"9087_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nature07986","volume":"458","author":"DR Green","year":"2009","unstructured":"Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127\u201330. https:\/\/doi.org\/10.1038\/nature07986.","journal-title":"Nature"},{"key":"9087_CR15","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.2627984100","volume":"100","author":"J Yu","year":"2003","unstructured":"Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA. 2003;100:1931\u20136. https:\/\/doi.org\/10.1073\/pnas.2627984100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9087_CR16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053\u20138. https:\/\/doi.org\/10.1126\/science.288.5468.1053.","journal-title":"Science"},{"key":"9087_CR17","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137:2721\u201335. https:\/\/doi.org\/10.1182\/blood.2020010167.","journal-title":"Blood"},{"key":"9087_CR18","first-page":"3131","volume":"54","author":"T Miyashita","year":"1994","unstructured":"Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131\u20135.","journal-title":"Cancer Res"},{"key":"9087_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.onc.1204067","volume":"20","author":"Y Wu","year":"2001","unstructured":"Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene. 2001;20:240\u201351. https:\/\/doi.org\/10.1038\/sj.onc.1204067.","journal-title":"Oncogene"},{"key":"9087_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010\u20134. https:\/\/doi.org\/10.1126\/science.1092734.","journal-title":"Science"},{"key":"9087_CR21","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1126\/science.1114297","volume":"309","author":"JE Chipuk","year":"2005","unstructured":"Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005;309:1732\u20135. https:\/\/doi.org\/10.1126\/science.1114297.","journal-title":"Science"},{"key":"9087_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ncb1123","volume":"6","author":"JIJ Leu","year":"2004","unstructured":"Leu JIJ, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004;6:443\u201350. https:\/\/doi.org\/10.1038\/ncb1123.","journal-title":"Nat Cell Biol"},{"key":"9087_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.devcel.2010.03.014","volume":"18","author":"SWG Tait","year":"2010","unstructured":"Tait SWG, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, Mu\u00f1oz-Pinedo C, et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell. 2010;18:802\u201313. https:\/\/doi.org\/10.1016\/j.devcel.2010.03.014.","journal-title":"Dev Cell"},{"key":"9087_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604. https:\/\/doi.org\/10.1126\/science.aax3649.","journal-title":"Science"},{"key":"9087_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671\u20138. https:\/\/doi.org\/10.1515\/hsz-2016-0107.","journal-title":"Biol Chem"},{"key":"9087_CR26","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","volume":"6","author":"RR Schimmer","year":"2022","unstructured":"Schimmer RR, Kovtonyuk LV, Klemm N, Fullin J, Stolz SM, Mueller J, et al. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Adv. 2022;6:3201\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021005859.","journal-title":"Blood Adv"},{"key":"9087_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","volume":"42","author":"ST Diepstraten","year":"2024","unstructured":"Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, et al. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42:850\u2013868.e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.004.","journal-title":"Cancer Cell"},{"key":"9087_CR28","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/febs.14505","volume":"285","author":"JE Conage-Pough","year":"2018","unstructured":"Conage-Pough JE, Boise LH. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. FEBS J. 2018;285:2626\u201340. https:\/\/doi.org\/10.1111\/febs.14505.","journal-title":"FEBS J"},{"key":"9087_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020;38:872\u2013890.e6. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.010.","journal-title":"Cancer Cell"},{"key":"9087_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transd Target Ther. 2022;7:1\u201313. https:\/\/doi.org\/10.1038\/s41392-021-00870-3.","journal-title":"Signal Transd Target Ther"},{"key":"9087_CR31","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res. 2016;22:4440\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3057.","journal-title":"Clin Cancer Res"},{"key":"9087_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00830-w","volume":"13","author":"BZ Carter","year":"2023","unstructured":"Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13:1\u201313. https:\/\/doi.org\/10.1038\/s41408-023-00830-w.","journal-title":"Blood Cancer J"},{"key":"9087_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med. 2023;3:154. https:\/\/doi.org\/10.1038\/s43856-023-00380-z.","journal-title":"Commun Med"},{"key":"9087_CR34","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1038\/sj.onc.1208793","volume":"24","author":"E Cepero","year":"2005","unstructured":"Cepero E, King AM, Coffey LM, Perez RG, Boise LH. Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. Oncogene. 2005;24:6354\u201366. https:\/\/doi.org\/10.1038\/sj.onc.1208793.","journal-title":"Oncogene"},{"key":"9087_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.200208089","volume":"160","author":"JE Ricci","year":"2003","unstructured":"Ricci JE, Gottlieb RA, Green DR. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biol. 2003;160:65\u201375. https:\/\/doi.org\/10.1083\/jcb.200208089.","journal-title":"J Cell Biol"},{"key":"9087_CR36","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1242\/jcs.073643","volume":"123","author":"SB Bratton","year":"2010","unstructured":"Bratton SB, Salvesen GS. Regulation of the Apaf-1\u2013caspase-9 apoptosome. J Cell Sci. 2010;123:3209. https:\/\/doi.org\/10.1242\/jcs.073643.","journal-title":"J Cell Sci"},{"key":"9087_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discov. 2019;9:890\u2013909. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0117.","journal-title":"Cancer Discov"},{"key":"9087_CR38","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019;9:910\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0125.","journal-title":"Cancer Discov"},{"key":"9087_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/2159-8290.CD-19-0510","volume":"9","author":"MR Savona","year":"2019","unstructured":"Savona MR, Rathmell JC. Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade. Cancer Discov. 2019;9:831\u20133. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0510.","journal-title":"Cancer Discov"},{"key":"9087_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh1436","volume":"9","author":"Y Nishida","year":"2023","unstructured":"Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, et al. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9:eadh1436. https:\/\/doi.org\/10.1126\/sciadv.adh1436.","journal-title":"Sci Adv"},{"key":"9087_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30481-7","volume":"13","author":"O Hassin","year":"2022","unstructured":"Hassin O, Nataraj NB, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun. 2022;13:2800. https:\/\/doi.org\/10.1038\/s41467-022-30481-7.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09087-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:49:24Z","timestamp":1792640964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09087-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9087"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09087-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L. owns stocks in Zentalis, Flash Therapeutics, Dialectic, and provided consultancy for Zentalis, Flash Therapeutics, Anji Onco, and Dialectic Therapeutics. R.C.L. provided consultancy for Takeda Pharmaceuticals, Bluebird bio, Qiagen, Sarepta Therapeutics, Verve Therapeutics, Jazz Pharmaceuticals, and Vertex Pharmaceuticals. L.H. owns stocks in and provides consultancy for Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"902"}}